

11 May 2021

**2021 Annual Meeting of Stockholders
– Chairman’s Address and Presentation by President and CEO**

Minnesota, United States and Melbourne, Australia – 11 May 2021 – Osprey Medical Inc. (ASX:OSP) (**Osprey or the Company**) is pleased to present the attached copy of the Chairman’s address and the presentation by the President and CEO which are to be delivered at the 2021 Annual Meeting of Stockholders to be held today, 11 May 2021 at 10.00am Australian Eastern Standard Time (Monday, 10 May 2021 at 7.00pm U.S. Central Daylight Time). Due to restrictions on travel and public gatherings associated with COVID-19, the Annual Meeting will be held as a virtual meeting.

To attend the virtual Annual Meeting, enter <https://agmlive.link/OSP21> into a web browser on your computer or online device.

- Stockholders will need a Shareholder Reference Number which will have been provided by Link Market Services;
- CDI holders will need their Shareholder Reference Number or Holder Identification Number printed at the top of the CDI Voting Instruction Form; and
- Proxyholders (including CDI holders who have appointed themselves as CDN’s¹ proxy) will need their proxy number which will have been provided by Link Market Services.

Further information on how to participate virtually is set out in the 2021 Proxy Statement.

This announcement has been approved by the President & Chief Executive Officer, Mike McCormick.

Contact details:

Investor relations

Ivan Lee
Vesparum Capital
T: (61) 3 8582 4800

ospreymed@vesparum.com

Company

Brendan Case
Company Secretary
M: (61) 410 442 393

brendan@casegovernance.com.au

About Osprey Medical (ASX: OSP)

Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient’s risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical’s Board and

¹ CHESS Depository Nominees Pty Limited is the holder of record for all shares beneficially owned by holders of CDIs

Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

OSPREY MEDICAL INC – 2021 ANNUAL MEETING OF STOCKHOLDERS

CHAIRMAN – MR JOHN ERB

Good morning ladies and gentlemen,

My name is John Erb and as Chairman of Osprey Medical I am pleased to welcome you to the 2021 Annual Meeting of stockholders which, due to COVID-19 restrictions around the globe, is being held as a virtual meeting provided by our share registrar, Link Market Services.

It is now 7.00pm, Monday, 10 May 2021 U.S. Central Daylight Time which is 10.00am, Tuesday, 11 May 2021 Australian Eastern Standard Time. I note that this is a properly constituted meeting and that a quorum is present. I therefore declare this Annual Meeting of Stockholders of Osprey Medical open.

I would like to first introduce our President and Chief Executive Officer, Mike McCormick. The other directors online today are Sandra Lesenfants, Neville Mitchell, and Chris Nave. Our Directors bring a diverse range of expertise and highly complementary skillsets to guide the overall progress of the Osprey Medical business.

Also online today are Nancy Ness, our Chief Financial Officer and Amanda Goar, CPA and Partner from the Company's Auditor, Baker, Tilly, Virchow, Krause, LLP. Amanda will be available to answer questions you may have about the conduct of the audit and the auditor's report.

Over the last year, COVID has presented many challenges for businesses globally, and Osprey was no exception to this both logistically and financially. A reduction in elective surgery and limited access to hospitals had a significant impact on our sales operations, which resulted in revenue decreasing from \$3.7m to \$1.7m. Despite these challenges, the agility of the company to implement new strategies resulted in focusing team efforts on stabilising the core commercial business, optimising our balance sheet, and evaluating new strategies for increasing the effectiveness of business operations. As a result of this agility, I am pleased to announce the latest financial results show positive momentum in our rebound from the effects of COVID with the latest

quarterly cash flow report indicating a 21% increase in total revenue vs prior quarter and even with prior year corresponding period.

When faced with the challenges of COVID, the business proactively responded by implementing a number of cost reduction initiatives which resulted in a 31% decline in total operating expenses compared to 2019. These cost-saving initiatives proved very successful and will carry forward throughout 2021, serving as a foundation for the company's long term cost-effective commercial strategy.

As part of these cost-saving measures, Osprey re-evaluated its US commercial structure and introduced a lean expansion strategy that leveraged our existing direct sales force in key geographies while introducing Independent Sales Agents (ISAs) to expand sales coverage in the US. The ISA strategy provides Osprey with a dual-pronged sales approach across the US, and the agreement has been structured to leverage the key advantages of both the ISA and direct sales force. Currently, our direct sales force covers 16 states, the introduction of these ISA agreements has resulted in coverage across an additional 26 states. We have already witnessed the positive impact of these ISA agreements, as we received our first order through BioCore Inc and expect sales to grow once full training has been completed.

Additionally, the Osprey team expanded its commercial reach outside of the US through its four-year strategic alliance with GE Healthcare. The DyeVert System will now be marketed in Europe, Russia, the Middle East, Africa, Central Asia, and Turkey through GE representatives to local hospitals and physicians. We received our first order in Q4 of 2020 through this partnership and another in Q1 2021, highlighting the success of the partnership so far for broad expansion into international markets.

In Australia and New Zealand, we also signed a three-year agreement with Australian-owned medical distribution company Regional Health Care Group. We also received first orders from this agreement in Q1 in 2021, representing a milestone for Osprey as the first commercial use of DyeVert technology in the region it was developed.

In 2020, we also continued to make advancements in other areas of the business with a number of impactful clinical and economic publications and product launches. Internationally, the DyeVert System received a MedTech Innovation Briefing in the UK, positioning it for a recommendation for

use to decrease AKI in 2021. In the US, three studies were published detailing the benefit of using the DyeVert System to reduce AKI in high-risk patients and the economic benefit of reducing hospital costs. Osprey also launched the DyeVert Power XT internationally, and received a CE Marking on this product. We were also the only cardiovascular supplier to receive a Supplier Horizon Award from Premier Inc, being recognised as a supplier who has made a positive impact in patient care while also lowering healthcare costs.

Alongside our performance as a company, we have also received many positive testimonials from medical professionals on the performance of our DyeVert technology which was been positively received. In the last year, Dr Keith Ellis, Director of Cardiovascular Services at Houston Methodist Sugarland Hospital was interviewed by Diagnostic & Interventional Cardiology (DAIC) on how to reduce COVID exposure, speed up exam times and cut re-admissions in cardiology departments, where he spoke to the role DyeVert technology has in this process. Dr Paul Tucker, a Cardiologist in Texas, and Dr Barry D. Bertolet an Interventional Cardiologist in Tupelo, have also publicly discussed the efficacy of the DyeVert system in reducing AKI events. This positive customer feedback from physicians highlights the efficacy of the system and how well it is being received by leading industry figures.

Regarding capital management, as of 31 December 2020, Osprey had a cash balance of A\$7.5m. During the year, we reported raising A\$15.6m through the Entitlement Offer, shortfall, and options exercised in connection with the Entitlement offer. Additionally, in 2020 Osprey secured a loan of A\$1.7m under the US Paycheck Protection Program (PPP) which we expect to be fully forgiven in 2021.

In the First Quarter of 2021 Osprey raised an additional A\$13.2m through the exercise of the options associated with the 2020 Entitlement Offer and A\$1.4m from a second loan under the US Paycheck Protection Program (PPP). The Company expects a significant portion of this loan to be forgiven, with the remaining amount subject to a 1% interest rate. As of March 31, 2021, Osprey had a cash balance of A\$ 17.7m. The capital raised combined with the cost-effective commercial strategy indicates the company is well funded to support the ongoing operations of the business and to achieve key milestones in 2021.

Despite a turbulent and difficult year in 2020, the agility and quick response from our management team has proved successful in mitigating the impact of COVID on Osprey. The cost-saving

initiatives implemented not only proved effective throughout the pandemic but remain beneficial strategies we can continue to employ throughout 2021 and the years that follow. We appreciate the confidence from our new and existing investors who have supported the Entitlement offer and shortfall raising. As we continue to recover from COVID, we are confident that the partnerships with the ISAs, GE Healthcare and RHCG will serve us well with expanding the DyeVert Technology into hospitals globally.


Before I conclude I would like to thank my fellow board members, our President and CEO Mike McCormick and the entire staff and management at Osprey Medical, for your continued dedication in ensuring the company's success.

I will now call upon Mike McCormick to outline our strategic priorities and further update you on Osprey's progress over the past twelve months.

Annual Meeting of Stockholders Osprey Medical

*To improve outcomes in chronic kidney disease (CKD)
patients, by preventing AKI, and lowering hospital costs*

CEO Presentation
May 2021



**be kind to
KIDNEYS**

Investment Highlights



Clear and large problem: Contrast-Induced Acute Kidney Injury (CI-AKI) is increasingly associated with poor patient outcomes and increased hospitals costs



Our technology is the solution: DyeVert has a ~\$1.1B addressable market¹ and is clinically proven to reduce the risk of CI-AKI through dye minimization and monitoring in angiographic procedures



Executing on US growth plan with significant whitespace ahead: Focus on increasing penetration in existing regions with direct salesforce while expanding coverage with addition of independent sales agents in new regions



Outside US becoming a material business following GE Healthcare partnership: Recently signed milestone distribution agreement with GE Healthcare across Europe and parts of Asia and another distribution agreement in Australia and New Zealand




A great value opportunity: Revenue and unit sales growth over past 5 years has not been reflected in share price

2020 defined by COVID but Osprey now well positioned for future growth

Key achievements in 2020

- Successful cost-reduction strategy with **31% reduction in operating expenses** compared to pcp
- Started lean expansion across US with **ISA strategy, now providing OSP access to ~80% of the US market¹**
- Milestone agreement with GE Healthcare for Europe and parts of Asia, **to provide OSP with material revenues OUS**
- **Entry into Australia and New Zealand via RHCG** distribution partner, marking Osprey's entry into the region where the technology was initially developed
- **CE Mark for DyeVert Power XT 2nd Generation** which provides access to the full market, with device compatible to power injection machines (covers the remaining ~40% of market)
- Osprey's technology featured in **key AKI reduction publications**

Performance since 2015²




Notes

1) 80% based on access to 42 states in US

2) Worldwide unit sales of DyeVert. Does not include other products such as DyeTect and Syringes. Revenue based on FY15 to FY20 audited company financials

Making angiography safer for Chronic Kidney Disease patients





Heart imaging requires the use of x-ray dye which is cleared by the kidney and can cause Contrast Induced Acute Kidney Injury (CI-AKI)

DYEVERT™

Osprey's technology is clinically proven to reduce CI-AKI, reducing dye volume by 40% without compromise to image quality

Osprey's DyeVert technology represents a significant market opportunity

Opportunity of 3.2M procedures per year in the USA and Western EU¹



Average selling price of DyeVert is ~US\$350

~US\$1.1B Market Potential

CI-AKI disease a deadly problem for patients and a costly issue for hospitals

Dye required in angiographic imaging procedures remains the underlying cause of CI-AKI



Patients

CI-AKI can have debilitating and life threatening consequences¹



Mortality post stenting is **61%** higher in CKD patients who had AKI events vs. those CKD patients who didn't have an AKI event³



Hospitals

15x

CI-AKI patients are 15 times more likely to be hospitalized over 4 days²

37%

CI-AKI patients have a 37% increase in 30-day readmissions³

US \$900m

Cost of CI-AKI to hospitals each year⁴

Notes

1) Tsai TT, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the NCDR Cath-PCI Registry. J Am Coll Cardiol Intv 2014;7:1-9Subramanian S, et al. Economic Burden of CIN: Implications for Prevention Strategies. Journal of Medical Economics. 2007;10:119-134.

2) Pfunter A, et al. Agency for Healthcare Research and Quality Statistical Brief #168. December 2013. <https://www.hcup-us.ahrq.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.pdf>

3) American Hospital Association Factsheet: Hospital Readmission Reduction Program. April 14, 2014. <http://www.aha.org/content/13/fs-readmissions.pdf>

3) A. Prasad, et al. - Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019

4) Adapted from A. Prasad et al, Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019 (in the US 200K CKD patients per year have CI-AKI at a cost of \$15K per event)

There is a concerted and growing focus on AKI avoidance

Physician consensus position on CI-AKI



American
Heart
Association®



Class 1 Level B recommendation
for CI-AKI reduction

Avoidance guidelines for at-risk patients




Screen

Patients with an eGFR < 60 ml/min are at high risk for AKI events



Hydrate

Adequate preparatory hydration should be given to at-risk patients




Reduce

Minimise contrast dosage to high risk patients


Burden of Illness study highlights costs of CI-AKI to patients and hospitals

A study of 749 hospitals with 2.8m angiography patients with CKD




AKI increases hospital costs¹

Index Procedure




AKI increases mortality in CKD patients



30-day
In-hospital mortality

AKI increases readmissions in CKD patients



30-day
All-cause readmission

AKI patients are more likely to be discharged to non-home facilities



5x

more likely to be discharged to hospice



2.8x

more likely to be discharged to nursing or rehab facility



2x

more likely to be transferred to acute care hospital

Notes

1) Mean observed charges

2) A. Prasad, et al. - Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019

Osprey's proprietary, patent-protected technology reduces dye by 40%

Osprey's proprietary solution

DYEVERT™

Clinically proven results



Clinically proven to reduce CI-AKI in at risk patients



Reduces dye in angiographic procedures by 40% without compromising image quality



Allow for real-time contrast monitoring of maximum allowable dose

A clear value proposition to hospitals

Osprey's "Be Kind to Kidneys" program rebates DyeVert Plus product costs to the extent these are not offset by savings related to CI-AKI reduction

Southeastern US Medical Center

| Cost of AKI to Hospital ^{1,2} | |
|---|-----------------------|
| Number of Annual Diagnostic and PCI Procedures | 6,376 |
| Risk Adjusted-AKI Rate per the NCDR Cath PCI Registry | 15% |
| Estimated Number of At-Risk Patients Developing AKI Annually | 956 |
| Cost per AKI Patient – Additional Length of Stay ^{1,2} | US\$12,000 |
| Total Annual Cost of AKI to Hospital | US\$11,472,000 |
| Device Cost to Hospital | |
| Number of Annual PCI's | 6,376 |
| DyeVert Plus (25% of Patients) | 1,594 |
| DyeVert Plus Price | US\$350 |
| Total Annual Device Cost to Hospital | US\$557,900 |

Clear value proposition

Notes

1) Subramanian, Jour Med Economics; 2007; 10:119-134.

2) Pfunter A, et al. Agency for Healthcare Research and Quality Statistical Brief #168. December 2013. <https://www.hcup-us.ahrq.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.pdf>.


Real-world AKI prevention strategies that work

AKI reduction initiatives

St. Mary's Medical Center
Huntington, WV
Presented at West Virginia ACC 2018 Annual Conference

25%
AKI Reduction*

* Compared to non-DyeVert group



Houston Methodist Sugarland Hospital
Sugarland, TX
Presented at ACC NCDR 2018 Annual Meeting


35%
Overall AKI Reduction



University Health System
San Antonio, TX
Presented at ACC Quality Summit 2019 Annual Meeting

63%
AKI Reduction*

* Compared to non-DyeVert group








Osprey Registry

up to 10K patients in 50 hospitals

Commercial initiatives positioning Osprey for global growth

Key activities over the past 6 months

| US ISA expansion | OUS expansion | Product development | Marketing and sales projects | Continued cost base optimisation |
|---|---|--|---|--|
|  <ul style="list-style-type: none"> ✓ Cost-effective expansion underway with several independent sales agency agreements signed ✓ Provides access to new states and complements existing salesforce which currently covers 16 states |  <ul style="list-style-type: none"> ✓ Milestone agreements with GE Healthcare and Regional Health Care Group signed in 2H CY20 ✓ Expected to provide Osprey with material revenues from OUS in 2021 and beyond |  <ul style="list-style-type: none"> ✓ CE Marking received for the 2nd generation DyeVert Power XT device and FDA clearance expected in early 2021 ✓ Product covers remaining 40% of market that prefer power injection machines |  <ul style="list-style-type: none"> ✓ Several publications and studies supporting the DyeVert System, showing reduction in CI-AKI by 51%-58% ✓ Recent studies provide Osprey and distribution partners with powerful marketing materials |  <ul style="list-style-type: none"> ✓ Cost reductions in place with a 31% reduction in operating expenses in 2H CY20 vs pcp ✓ US and OUS expansions in line with lean and cost-efficient business model going forward |


2021 US priority: expanding geographic reach to include ~80% of market

Strong presence and customer adoption through direct salesforce in recent years

- Direct salesforce has provided Osprey with significant growth in US over the years
- Strong presence currently covering 16 states

Now expanding footprint through cost-effective, results-driven Independent Sales Agency (ISA) agreements

- ISA expansion in line with company's lean and cost-efficient business model, with sales agents paid by commission
- Recent ISA agreements signed (since Nov-20), providing coverage to 26 new states




2021 OUS priority: targeting material sales from milestone agreements

1 GE Healthcare Agreement

- ✓ 4-year agreement signed in 3Q-20 for exclusive distribution in Europe and Asia
- ✓ Minimum purchase levels established that escalate each year and are required for GE to maintain exclusive rights
- ✓ Transfer prices fixed which provide appropriate Gross Margin returns

Strong DyeVert launch in 1Q despite COVID challenges in EU. Osprey expects GE sales to add >18% to total revenues in 2021



2 RHCG Agreement


- ✓ 3-year agreement signed in Sept-20 for exclusive distribution in Australia and New Zealand
- ✓ Minimum purchase levels and fixed transfer prices
- ✓ Strategically important markets with the DyeVert technology originating from Australia

First sales expected in the near-term upon completion of training of distributor salesforce

Significant global expansion in 2021 underpins Osprey's exciting outlook



2020 sales coverage



2021 sales coverage

Well positioned for growth with optimised marketing collateral in place

Increased AKI awareness and strong focus on DyeVert...

Increased AKI awareness in industry

Cardiology Societies AKI reduction guidelines call for contrast reduction; DyeVert is the only FDA approved dye reduction device

Growing clinical support for DyeVert

Multiple Independent, peer-reviewed studies showing 51-58% Mean AKI reduction with DyeVert¹

Clear value proposition demonstrated

Osprey's patient outcome rebate - If AKI does not decline in the first 6 months of DyeVert use Osprey will rebate the hospital for DyeVert purchases


... provides high-value direct marketing collateral

Accessing the entire market of heart imaging procedures with DyeVert

Use with hand injection




Use with power injection



DYEVERT™
Contrast Reduction System **PLUS EZ**

Approximately 60%
worldwide market



DYEVERT™
Contrast Reduction System **POWER XT**

Approximately 40%
worldwide market

FDA pending,
expected in 2021

Disclaimer

This presentation has been prepared by Osprey Medical, Inc. (“Osprey” or the “Company”) for the sole purpose of providing general and background information on Osprey. This presentation does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation by any person to sell or apply for securities in Osprey in any jurisdiction, and none of this presentation document or its contents shall form the basis of any contract or commitment. This presentation is not intended to constitute legal, tax or accounting advice or opinion, or financial product advice and should not be relied upon as a representation of any matter that a person should consider in evaluating Osprey. You must not rely on the presentation provided but make your own independent assessment of the presentation and seek and rely upon your own independent taxation, legal, financial or other professional advice in relation to the presentation. This presentation does not take into account an your investment objectives, taxation situation, financial situation or needs. Osprey is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Osprey securities.

None of Osprey, its officers, directors, employees and agents, nor any other person makes any representation or warranty, express or implied, as to, or endorsement of, Osprey, the accuracy or completeness of any information, statements or representations contained in this presentation and none of them accepts any responsibility or liability for any errors or omissions in this presentation whatsoever.

The information in this presentation is subject to change without notice and Osprey does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements which involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Osprey to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

All figures in the presentation are A\$ thousands on a constant currency basis based on an exchange rates of A\$1: US\$0.71 unless stated otherwise and all market shares are estimates only. The pro-forma historical financial information included in this presentation does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the US Securities and Exchange Commission. This presentation may contain certain financial data that is "non-GAAP financial measures" under Regulation G under the U.S. Securities Exchange Act of 1934, as amended. The disclosure of such non-GAAP financial measures in the manner included in this presentation would not be permissible in a registration statement under the Securities Act. These non-GAAP financial measures do not have a standardised meaning prescribed by AIFRS and, therefore, may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with AIFRS. Although we believe these non-GAAP financial measures provide useful information to users in measuring the financial performance and condition of our business for the reasons set out in this presentation, you are cautioned not to placed undue reliance on any non-GAAP financial measures and ratios included in this presentation.

DyeVert™, DyeVert Plus and DyeTect Systems Regulatory Status: Europe – CE Mark obtained; Australia – TGA approval obtained; United States – 510(k) cleared.



Company
Brendan Case

Company Secretary

E: brendan@casegovernance.com.au

T: +61 410 442 393

Investor Relations
Ivan Lee

Vesparum Capital

E: ospreymed@vesparum.com

T: +61 3 8582 4800